Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of Cerebrolysin™ in Patients With Aneurysmal Subarachnoid Hemorrhage

Exclusion Criteria

• •1. Unsalvageable patients: fixed and dilated pupils after resuscitation or signs of brainstem herniation that precludes definitive therapy.
• •2. No previous history of Cerebrolysin™ exposure.
• •3. No known allergy to Cerebrolysin™ or porcine tissue-derived products.
• •4. Pregnancy or breast feeding.
• •5. Evidence of pre-existing major health problems
• •6. Suspected or known additional disease process that threatens life expectancy, for example malignancy.
• •7. Known or strong suspicion of drug dependency including alcohol
• •8. Known epilepsy
• •9. Any neurological or non-neurological condition independent from SAH that might influence the functional outcome or other efficacy outcome measures